SCHEMBL347902

SCHEMBL347902

CCOC(=O)c1csc(CN2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.44
ACKR3 P25106 2/20 0.44
NPC1 O15118 3/20 0.44
MAPT P10636 3/20 0.44
RAB9A P51151 3/20 0.44
HSP90AA1 P07900 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
ABCB1 P08183 1/20 0.42
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
KDM4E B2RXH2 1/20 0.41
PIK3CD O00329 1/20 0.41
EED O75530 1/20 0.41
RBBP4 Q09028 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265007 0.86 ACKR3 (0.49) HRH3ACKR3PIK3CD
SCHEMBL348893 0.84 HRH3 (0.46) HRH3ACKR3MAPTALDH1A1LMNA
SCHEMBL348818 0.83 ACKR3 (0.51) HRH3ACKR3ALDH1A1PIK3CDEED
SCHEMBL1118133 0.82 LMNA (0.52) HRH3ACKR3NPC1MAPTRAB9A
SCHEMBL13458583 0.82 HRH3 (0.46) HRH3ACKR3PIK3CD
SCHEMBL10425978 0.81 HRH3 (0.57) HRH3NPC1MAPTRAB9AHSP90AA1
SCHEMBL2618737 0.81 IDO1 (0.44) ACKR3SMN1; SMN2HSD17B10ALDH1A1KDM4E
SCHEMBL13458732 0.79 BAZ2A (0.51) HRH3NPC1MAPTRAB9AHSP90AA1
SCHEMBL1431790 0.79 HRH3 (0.58) HRH3NPC1MAPTRAB9AHSP90AA1
SCHEMBL5233223 0.79 LMNA (0.48) HRH3NPC1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 EP disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed
EP-2318368-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. Organon (NL) 2011-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES NPC1, ABCB11, NPC1L1 HRH3 1328/4885ACKR3 1675/4885NPC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.